CytomX Therapeutics (CTMX) Return on Sales (2014 - 2026)

CytomX Therapeutics has reported Return on Sales for 13 years, with the latest figure at 0.02% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales fell 2.0% year-over-year to 0.02%; the trailing twelve-month figure through Mar 2026 stood at 0.02% (down 2.0% YoY), and the FY2025 full-year result was 0.0%, changed 0.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.02%, up from 0.4% in the prior quarter.
• The five-year high for Return on Sales was 0.0% in Q4 2024, with the low at 0.4% in Q4 2025.
• Historically, Return on Sales has averaged 0.03% across 5 years, with a median of 0.0% in 2023.
• Annual changes were most pronounced in 2022 — Return on Sales increased 3 bps — and 2025, when it plunged 40 bps.
• CytomX Therapeutics' Return on Sales stood at 0.0% in 2022, then surged by 107 bps to 0.0% in 2023, then surged by 1475 bps to 0.0% in 2024, then plunged by 8169 bps to 0.4% in 2025, then soared by 96 bps to 0.02% in 2026.
• The last three Return on Sales figures came in at 0.02% (Q1 2026), 0.4% (Q4 2025), and 0.02% (Q3 2025), per Business Quant data.